Novavax, Inc.
-
Ticker
NVAX
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 501-1000 Employees
- Based in Gaithersburg, Maryland
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform (VLP) technology. It develops vaccine product candidates that target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; and respiratory syncytial virus (RSV).
REPORT RATINGS
4.8 / 5.0 (168)
Novavax, Inc. reports have an aggregate usefulness score of 4.8 based on 168 reviews.
Novavax, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports